SWOG clinical trial number
SWOG-9040
Intergroup Rectal Adjuvant Protocol, A Phase III Study
Closed
Phase
Published
Abbreviated Title
Intergroup Rectal Adjuvant Protocol, A Phase III Study
Activated
09/15/1990
Closed
11/22/1992
Research committees
Gastrointestinal Cancer
Publication Information Expand/Collapse
2002
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of Intergroup 0114
2001
Impact of number of nodes retrieved on outcome in patients with rectal cancer.
Impact of TNM stage on survival and disease control in adjuvant rectal cancer pooled analysis
1997
Adjuvant postoperative fluorouracil modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114.
1996
Toxicity in the adjuvant therapy of rectal cancer: A preliminary report of Intergropu 0114 (CALGB 9081).
Other Clinical Trials
SWOG Clinical Trial Number
S2303
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2104
A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10/14/2021
Accrual
54%
Open
Phase